IBUPROHM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for IBUPROHM (IBUPROHM).
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, thereby decreasing pain, inflammation, and fever.
| Metabolism | Hepatic via CYP2C9; metabolites are glucuronidated and excreted renally. |
| Excretion | Renal: 90% as metabolites (mostly glucuronide conjugates) and unchanged drug (1%); biliary/fecal: <5%. |
| Half-life | 2-4 hours in adults; prolonged to 1.5-2.5 hours in neonates? Actually: terminal half-life ~2-4 h in adults, up to 12 h in overdose; context: requires frequent dosing. |
| Protein binding | >99% bound to albumin primarily, also alpha1-acid glycoprotein. |
| Volume of Distribution | 0.1-0.2 L/kg; indicates low tissue distribution, primarily in plasma and extracellular fluid. |
| Bioavailability | Oral: 80-100%; rectal: 80-90% relative to oral; topical: <10% systemically absorbed. |
| Onset of Action | Oral: 30-60 min; topical: 1-2 h for local effect; rectal: similar to oral. |
| Duration of Action | Oral: 4-6 h for analgesia/antipyretic; anti-inflammatory effect requires longer dosing; topical: 4-8 h. |
| Molecular Weight | 206.28 |
200-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day.
| Dosage form | TABLET |
| Renal impairment | eGFR 30-59 mL/min: reduce dose by 25-50% and avoid doses >400 mg; eGFR <30 mL/min: avoid use or use with extreme caution at lowest effective dose. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use. |
| Pediatric use | Children 6 months to 12 years: 5-10 mg/kg/dose every 6-8 hours; maximum 40 mg/kg/day or 2000 mg/day, whichever is less. |
| Geriatric use | Initiate at lowest effective dose (200 mg every 8-12 hours); maximum 1200 mg/day; monitor renal function and gastrointestinal bleeding risk. |
| 1st trimester | Avoid; associated with increased risk of miscarriage and congenital malformations (especially cardiac defects) when used during first trimester. |
| 2nd trimester | Avoid; use only if clearly needed and benefit outweighs risk. May cause oligohydramnios and fetal renal impairment. |
| 3rd trimester | Contraindicated; known to cause premature closure of ductus arteriosus, oligohydramnios, and neonatal pulmonary hypertension. |
Clinical note
Comprehensive clinical and safety monograph for IBUPROHM (IBUPROHM).
| Placental transfer | Ibuprofen crosses the placenta by passive diffusion. Fetal-to-maternal plasma concentration ratio is approximately 0.5–0.9. Detectable in fetal serum and amniotic fluid. |
| Breastfeeding | Ibuprofen is excreted into breast milk in very small amounts (less than 1% of maternal dose). The American Academy of Pediatrics considers it compatible with breastfeeding. However, use lowest effective dose for shortest duration, and monitor infant for potential adverse effects (e.g., gastrointestinal upset, rash). |
■ FDA Black Box Warning
Cardiovascular thrombotic events risk; gastrointestinal bleeding risk.
| Serious Effects |
History of allergic reaction to ibuprofen or other NSAIDsHistory of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDsPerioperative pain in the setting of coronary artery bypass graft (CABG) surgeryActive gastrointestinal bleeding or peptic ulcer diseaseSevere renal impairment (eGFR < 30 mL/min/1.73 m²)Severe hepatic impairment (Child-Pugh class C)Third trimester of pregnancy
| Precautions | Cardiovascular events, GI bleeding, renal toxicity, hypertension, fluid retention, anaphylactoid reactions, hepatic impairment, asthma exacerbation, pregnancy (third trimester). |
| Food/Dietary | The absorption of IBUPROHM may be delayed when taken with food, but overall extent of absorption is unchanged. To reduce GI irritation, it is recommended to take with food or milk. Avoid alcohol as it increases risk of GI bleeding. Grapefruit juice has no significant interaction. Caffeine may add to stimulatory effects but not a direct interaction. |
Loading safety data…
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | First trimester: Avoid use; NSAIDs are associated with increased risk of miscarriage and cardiac defects. Second trimester: Use with caution; no clear evidence of major malformations but potential for oligohydramnios. Third trimester: Contraindicated; risk of premature closure of ductus arteriosus, fetal renal impairment, and oligohydramnios. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function (serum creatinine, BUN), and signs of fluid retention. Fetal monitoring includes ultrasound for amniotic fluid volume (especially with prolonged use), and fetal echocardiography if used after 28 weeks gestation. |
| Fertility Effects | Ibuprofen may impair female fertility by interfering with prostaglandin synthesis, affecting ovulation and implantation. Reversible upon discontinuation. No significant effect on male fertility has been documented. |
| Clinical Pearls | IBUPROHM is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic, and anti-inflammatory properties. Use lowest effective dose for shortest duration to minimize GI and cardiovascular risk. Contraindicated in patients with history of asthma, urticaria, or allergic reactions to aspirin or other NSAIDs. Monitor renal function in elderly, dehydrated, or those on diuretics/ACE inhibitors. May mask signs of infection. Do not combine with other NSAIDs or anticoagulants without careful monitoring. |
| Patient Advice | Take with food or milk to reduce stomach upset. · Do not exceed recommended dose or duration. · Avoid alcohol while taking this medication. · Stop use and contact doctor if you experience chest pain, weakness, slurred speech, or signs of stomach bleeding (e.g., black/bloody stools, vomiting blood). · Tell your doctor about all medications you take, especially blood thinners, aspirin, or other NSAIDs. · Do not use if you have ever had an allergic reaction to aspirin or any NSAID. · Store at room temperature away from moisture and heat. |